111 (NASDAQ:YI) versus MDxHealth (NASDAQ:MDXH) Financial Review

MDxHealth (NASDAQ:MDXH) and 111 (NASDAQ:YI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Earnings and Valuation

This table compares MDxHealth and 111″s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$90.05 million	1.74	-$38.07 million	($0.64)	-5.19
111	$1.97 billion	0.02	-$1.42 million	($0.84)	-4.30

111 has higher revenue and earnings than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares MDxHealth and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MDxHealth	-30.50%	-1,078.01%	-20.05%
111	-0.52%	N/A	-2.72%

Insider and Institutional Ownership

21.3% of 111 shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by insiders. Comparatively, 43.9% of 111 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for MDxHealth and 111, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1	0	4	0	2.60
111	1	0	0	0	1.00

MDxHealth currently has a consensus target price of $7.75, indicating a potential upside of 133.43%. Given MDxHealth’s stronger consensus rating and higher possible upside, equities analysts clearly believe MDxHealth is more favorable than 111.

Volatility & Risk

MDxHealth has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.

Summary

111 beats MDxHealth on 8 of the 14 factors compared between the two stocks.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.